This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Meyer LA , Cronin AM , Sun CC , Bixel K , Bookman MA , Cristea MC , Griggs JJ , Levenback CF , Burger RA , Mantia-Smaldone G , Matulonis UA , Niland JC , O'Malley DM , Wright AA
Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer
J Clin Oncol. 2016 Sep 6;34(32) :3854-3863
PMID: 27601552 PMCID: PMC5477982 URL: https://www.ncbi.nlm.nih.gov/pubmed/27601552
AbstractPURPOSE: In 2010, a randomized clinical trial demonstrated noninferior survival for patients with advanced ovarian cancer who were treated with neoadjuvant chemotherapy (NACT) compared with primary cytoreductive surgery (PCS). We examined the use and effectiveness of NACT in clinical practice. PATIENTS AND METHODS: A multi-institutional observational study of 1,538 women with stages IIIC to IV ovarian cancer who were treated at six National Cancer Institute-designated cancer centers. We examined NACT use in patients who were diagnosed between 2003 and 2012 (N = 1,538) and compared overall survival (OS), morbidity, and postoperative residual disease in a propensity-score matched sample of patients (N = 594). RESULTS: NACT use increased from 16% during 2003 to 2010 to 34% during 2011 to 2012 in stage IIIC disease (Ptrend < .001), and from 41% to 62% in stage IV disease (Ptrend < .001). Adoption of NACT varied by institution, from 8% to 30% for stage IIIC disease (P < .001) and from 27% to 61% (P = .007) for stage IV disease during this time period. In the matched sample, NACT was associated with shorter OS in stage IIIC disease (median OS: 33 v 43 months; hazard ratio [HR], 1.40; 95% CI, 1.11 to 1.77) compared with PCS, but not stage IV disease (median OS: 31 v 36 months; HR, 1.16; 95% CI, 0.89 to 1.52). Patients with stages IIIC and IV disease who received NACT were less likely to have >/= 1 cm postoperative residual disease, an intensive care unit admission, or a rehospitalization (all P </= .04) compared with those who received PCS treatment. However, among women with stage IIIC disease who achieved microscopic or </= 1 cm postoperative residual disease, NACT was associated with decreased OS (HR, 1.49; 95% CI, 1.01 to 2.18; P = .04). CONCLUSION: Use of NACT increased significantly between 2003 and 2012. In this observational study, PCS was associated with increased survival in stage IIIC, but not stage IV disease. Future studies should prospectively consider the efficacy of NACT by extent of residual disease in unselected patients.
NotesMeyer, Larissa A Cronin, Angel M Sun, Charlotte C Bixel, Kristin Bookman, Michael A Cristea, Mihaela C Griggs, Jennifer J Levenback, Charles F Burger, Robert A Mantia-Smaldone, Gina Matulonis, Ursula A Niland, Joyce C O'Malley, David M Wright, Alexi A J Clin Oncol. 2016 Sep 6. pii: JCO681239.